FDA Approved: COTEMPLA XR-ODT — Supplemental Application (Neos Therapeutics Brands, LLC)

View source ↗

Summary

The FDA approved a supplemental NDA for Cotempla XR-ODT, a methylphenidate product from Neos Therapeutics Brands, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• COTEMPLA XR-ODT (METHYLPHENIDATE)

Snippet

SUPPL AP for COTEMPLA XR-ODT (METHYLPHENIDATE)